Home | Medical Need | R&D Programmes | Company | Collaborations | News |
Multi-resistant bacteria at large
In the U.S. alone, 99 000 patients per year die from hospital-acquired infections, most often caused by multi-drug resistant bacteria. Fortunately, new effective antibiotics have been developed against multi-resistant Gram-positive bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus faecalis (VRE), but about half of the hospital-acquired infections are caused by Gram-negatives.
Northern Antibiotics fights against multi-resistant Gram-negatives
Northern Antibiotics has developed two series of novel compounds which are highly effective against difficult-to-treat Gram-negative bacteria including multi-resistant Escherichia coli, Klebsiella pneumoniae, other species of Enterobacteriaceae, and Acinetobacter baumannii.

We come from Finland
Northern Antibiotics is a venture-capital-backed R&D company founded in 2003. Professor Martti Vaara, M.D., Ph.D., co-founder of the company, is a broadly acknowledged expert in the outer membrane of Gram-negative bacteria.
Collaborations on four continents
Rather than investing heavily in its own infrastructure, Northern Antibiotics outsources most of the laboratory research to academic groups and contract research organizations, each world-renowned in its own field of expertise.
  Northern Antibiotics Ltd
Tekniikantie 14 (Technopolis, Innopoli 2) Suite A111, FIN-02150 Espoo, Finland
Phone: +358-50-355 0822
E-mail: admin@northernantibiotics.com
  Copyright © 2007-2018 Northern Antibiotics Ltd